Evidence map›Paper›PMID 40249500›Full record

ReviewPharmacological reports : PR2025

Calycosin and kidney health: a molecular perspective on its protective mechanisms.

Diksha Dalal, Lovedeep Singh, Anish Singh

Abstract readReview
PubMed Publisher
In one paragraph

Review in Pharmacological reports : PR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Renal failure · 2026
    Trial
  2. Article
  3. Article
  4. Review
  5. Asiatic acid fromFrontiers in nutrition · 2026
    Article
  6. Article
  7. Article
  8. The Role of Sirt3 in Kidney Health and Disease.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Diksha DalalUniversity Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India.
Lovedeep SinghUniversity Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India. lovedeep992s@gmail.com.ORCID https://orcid.org/0000-0002-2903-4293
Anish SinghUniversity Institute of Pharma Sciences, Chandigarh University, Mohali, Punjab, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney diseases encompass a diverse group of pathological conditions characterized by the progressive loss of renal function, leading to systemic complications and increased morbidity. Their global prevalence increasing, posing a substantial public health challenge. The underlying pathophysiology involves complex molecular interactions that drive inflammation, fibrosis, and tissue injury. Notably, the AGE/RAGE axis activates NF-κB, a pivotal transcription factor responsible for pro-inflammatory cytokine production. This response is further intensified by NLRP3-inflammasome activation, which detects cellular stress and promotes IL-1β release. Additionally, TGF-β signaling through SMADs and MAPK pathways induces ECM accumulation, contributing to tissue fibrosis. Besides this, oxidative stress-induced ferroptosis and apoptosis also play critical roles in disease progression. Given the multifactorial nature of kidney diseases, agents with multi-targeted actions are promising for effective renoprotection. Significant research interest has emerged in exploring calycosin's protective effects against kidney-related pathologies, owing to its diverse pharmacological properties, including anti-inflammatory, antioxidant, anti-apoptotic, and anti-fibrotic effects. Calycosin is a naturally occurring isoflavone primarily found in Astragalus membranaceus, a well-known medicinal herb in traditional Chinese medicine. Several studies have demonstrated that calycosin exerts its renoprotective effects by modulating key molecular mediators, including RAGE, NF-κB, TGF-β, MAPKs, NLRP3-inflammasome, Nrf-2, PPARγ, and Sirtuin-3, among others, thereby providing a multitargeted defense against kidney diseases. Considering the potential of calycosin in modulating these mediators, the present study was conceptualized to study the mechanistic interplay underlying its renoprotective effects. By investigating these interconnected pathways, this study will provide foundational insights that will enable future researchers to address existing gaps and further elucidate calycosin's potential in renal disorders.

Indexed as

IsoflavonesKidneyKidney DiseasesProtective AgentsAnimalsAnti-Inflammatory AgentsFibrosisHumansInflammasomesOxidative StressSignal Transduction7,3'-dihydroxy-4'-methoxyisoflavoneAnti-Inflammatory AgentsInflammasomesIsoflavonesProtective AgentsCalycosinKidneyNF-κBNrf-2RAGETGF-β

Identifiers

PMID40249500

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.